Todd DeFor
Overview
Explore the profile of Todd DeFor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1833
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shaffer B, Gooptu M, DeFor T, Spellman S, Stefanski H, Shaw B, et al.
J Clin Oncol
. 2024 Nov;
43(4):476-478.
PMID: 39504503
No abstract available.
2.
Merino A, Shanley R, Rashid F, Langer J, Dolan M, Tu S, et al.
Front Immunol
. 2024 Mar;
15:1310752.
PMID: 38504993
Background: Melphalan is the most common conditioning regimen used prior to autologous stem cell transplant (ASCT); however, there are varying data on optimal melphalan timing prior to transplant for best...
3.
Schultz B, Miller D, DeFor T, Blazar B, Panoskaltsis-Mortari A, Betts B, et al.
J Cutan Pathol
. 2022 Feb;
49(6):532-535.
PMID: 35224759
Background: Amphiregulin (AREG) is increased in circulation in acute graft-versus-host disease (aGVHD) and is associated with poor steroid response and lower survival. The expression of AREG in aGVHD target organs...
4.
Subramanian S, Cohn C, DeFor T, Welbig J, Brunstein C, Jurdi N, et al.
Transfusion
. 2021 Apr;
61(7):2064-2074.
PMID: 33899243
Background: Transfusions are essential for allogeneic hematopoietic cell transplant (HCT), yet they are influenced by graft, donor, and other factors. Study Design: We analyzed transfusions in 165 adult reduced intensity...
5.
Okoev G, Weisdorf D, Wagner J, Blazar B, MacMillan M, DeFor T, et al.
Bone Marrow Transplant
. 2021 Jan;
56(6):1373-1380.
PMID: 33420387
We compared chronic graft-versus-host disease (cGvHD) following umbilical cord blood (UCBT) and matched sibling donor peripheral blood transplant (MSD). 145 patients (2010-2017) with cGvHD after MSD (n = 104) and...
6.
Jurdi N, Rogosheske J, DeFor T, Bejanyan N, Arora M, Bachanova V, et al.
Transplant Cell Ther
. 2020 Oct;
27(1):84.e1-84.e5.
PMID: 33053448
The high incidence of human herpesvirus-6 (HHV-6) reactivation, potentially interfering with engraftment after umbilical cord blood (UCB) hematopoietic cell transplantation (HCT), remains a major challenge. To potentially address this problem,...
7.
Jurdi N, DeFor T, Adamusiak A, Brunstein C, Pruett T, Weisdorf D
Transplant Cell Ther
. 2020 Sep;
27(1):87.e1-87.e6.
PMID: 32949755
There is a growing population of transplant survivors receiving both a solid organ transplantation (SOT) and a hematopoietic cell transplantation (HCT). This group remains underreported and not well described. We...
8.
Kulkarni A, Ebadi M, Zhang S, Meybodi M, Ali A, DeFor T, et al.
ESMO Open
. 2020 Sep;
5(5):e000803.
PMID: 32900789
Background: In solid tumours, antibiotic use during immune checkpoint inhibitor (ICI) treatment is associated with shorter survival. Following allogeneic haematopoietic cell transplantation (allo-HCT), antibiotic-induced gut microbiome alterations are associated with...
9.
Hussein E, DeFor T, Wagner J, Sumstad D, Brunstein C, McKenna D
Transfusion
. 2019 Nov;
60(1):144-154.
PMID: 31756003
Background: The CFU assay is considered the only in vitro assay that assesses the biologic function of hematopoietic stem and progenitor cells (HSPC). Study Design And Methods: To investigate the...
10.
Pilbeam K, Wang H, Taras E, Bergerson R, Ettestad B, DeFor T, et al.
Oncotarget
. 2018 Mar;
9(15):11938-11947.
PMID: 29552283
Children with high risk sarcoma have a poor prognosis despite surgical resection, irradiation and chemotherapy. Alternative therapies are urgently needed. Urokinase-type plasminogen activator receptor (uPAR) and epidermal growth factor receptor...